<DOC>
	<DOCNO>NCT02194309</DOCNO>
	<brief_summary>To investigate safety , tolerability , pharmacokinetics telmisartan amlodipine follow single administration 40 mg telmisartan/5 mg amlodipine 80 mg telmisartan/5 mg amlodipine , subsequently , follow multiple administration 40 mg telmisartan/5 mg amlodipine 80 mg telmisartan/5 mg amlodipine daily 10 day</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Multiple Oral Doses 40 mg Telmisartan/5 mg Amlodipine 80 mg Telmisartan/5 mg Amlodipine Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Healthy male volunteer accord follow criterion : 1 . No find deviate clinical relevance evidence clinically relevant concomitant disease base upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate , body temperature ) , 12lead ECG , clinical laboratory test 2 . Age ≥20 Age ≤35 year 3 . Body weight ≥50 kg 4 . Body mass index ( BMI ) ≥17.6 BMI ≤26.4 kg/m2 5 . Signed date write informed consent admission trial 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 3 . Chronic relevant acute infection 4 . Any clinical relevant finding laboratory test deviate normal 5 . Positive result either hepatitis B surface antigen ( HBsAg ) , anti hepatitis C virus ( HCV ) antibody , syphilitic test human immunodeficiency virus ( HIV ) test 6 . History surgery gastrointestinal tract ( except appendectomy ) 7 . History relevant orthostatic hypotension ( mean stand systolic blood pressure ( SBP ) vary ≥20 mmHg mean supine SBP mean stand diastolic blood pressure ( DBP ) vary ≥10 mmHg mean supine DBP ) , faint spell blackouts 8 . History hepatic dysfunction ( e.g. , biliary cirrhosis , cholestasis ) 9 . History serious renal dysfunction 10 . History bilateral renal artery stenosis renal artery stenosis solitary kidney 11 . History cerebrovascular disorder 12 . History hyperkalemia 13 . Known hypersensitivity component formulation , Angiotensin Receptor Blocker ( ARB ) , angiotensin convert enzyme dihydropyridine 14 . Intake drug long halflife ( ≥24 hour ) within least one month le 10 halflives respective drug administration trial 15 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 7 day administration trial 16 . Participation another trial investigational drug within 4 month 6 halflives investigational drug administration 17 . Smoker ( ≥20 cigarettes/day ) 18 . Alcohol abuse ( 60 g ethanol/day : ex . 3 middlesized bottle beer , 3 gous ( equivalent 540 mL ) sake ) 19 . Drug abuse 20 . Blood donation ( 100 mL within 4 week administration trial ) 21 . Excessive physical activity ( within 1 week administration trial ) 22 . Intake alcohol within 2 day administration 23 . Inability comply dietary regimen trial centre 24 . Intake drugs/supplements ingredient hypericum perforatum ( citrus fruit , Sevilla orange ) within 5 day prior administration 25 . Inability refrain smoke trial day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>